- TherapeuticsMD recently reported a strong Q3 earnings with a beat on EPS and revenue. The company was able to fight through the COVID-19 headwinds to surpass Q2's commercial numbers.
- It appears the company will be able to hit their Q4 revenue covenant with their lender. In addition, the company is looking to divest vitaCare to unlock some non-dilutive financing.
- Sadly, the company announced another public offering that will once again dilute shareholders at an abysmal share price.
- I review the company's Q3 numbers and discuss my plans for my bloated TXMD position.
For further details see:
TherapeuticsMD: Q3 Report Reveals Strong Rebound And Bolsters Commercial Outlook